Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

High-dose therapy and innovative approaches to treatment of multiple myeloma.

Barlogie B.

Semin Hematol. 2001 Apr;38(2 Suppl 3):21-7. Review.

PMID:
11309705
2.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
3.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
4.

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J.

Blood. 2000 Jun 15;95(12):4008-10.

6.

[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.

PMID:
14556449
7.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.

Hematol J. 2002;3(4):185-92.

PMID:
12189564
8.

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.

Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B.

Br J Haematol. 2002 Jan;116(1):211-7.

PMID:
11841419
9.

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.

Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G.

Br J Haematol. 2002 Oct;119(1):164-8.

PMID:
12358921
10.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

11.

Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.

Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler TM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):475-81.

12.

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.

Alexanian R, Weber D, Giralt S, Delasalle K.

Ann Oncol. 2002 Jul;13(7):1116-9.

13.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G.

Blood. 2001 Jul 15;98(2):492-4.

14.

Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features.

Kaufmann H, Ackermann J, Greinix H, Nösslinger T, Gisslinger H, Keck A, Ludwig H, Worel N, Kalhs P, Zielinski C, Drach J.

Ann Oncol. 2003 Nov;14(11):1667-72.

16.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

17.

Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

Ballestrero A, Ferrando F, Miglino M, Clavio M, Gonella R, Garuti A, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F.

Eur J Haematol. 2002 Feb;68(2):101-6.

PMID:
12038448
18.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

19.

The role of stem cell transplantation in multiple myeloma.

Harousseau JL, Attal M.

Blood Rev. 2002 Dec;16(4):245-53. Review.

PMID:
12350367
20.

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr.

Br J Haematol. 2007 Jul;138(2):176-85.

PMID:
17593024
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk